HRP20171194T1 - Trovalentni konstrukti nanotijela protiv ljudskog respiratornog sincicijskog virusa (hrsv) za prevenciju i/ili liječenje infekcija dišnih puteva - Google Patents

Trovalentni konstrukti nanotijela protiv ljudskog respiratornog sincicijskog virusa (hrsv) za prevenciju i/ili liječenje infekcija dišnih puteva Download PDF

Info

Publication number
HRP20171194T1
HRP20171194T1 HRP20171194TT HRP20171194T HRP20171194T1 HR P20171194 T1 HRP20171194 T1 HR P20171194T1 HR P20171194T T HRP20171194T T HR P20171194TT HR P20171194 T HRP20171194 T HR P20171194T HR P20171194 T1 HRP20171194 T1 HR P20171194T1
Authority
HR
Croatia
Prior art keywords
amino acid
gln108leu
seq
arg105gln
asp85glu
Prior art date
Application number
HRP20171194TT
Other languages
English (en)
Inventor
Erik Depla
Catelijne Stortelers
Stephanie Staelens
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of HRP20171194T1 publication Critical patent/HRP20171194T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

1. Trovalentni polipeptid koji je usmjeren protiv proteina F iz hRSV, koji se bira iz bilo kojeg od (A) do (C): (A) trovalentnog polipeptida koji se bira između sljedećih polipeptida: a) SEQ ID Br.: 142-145 i 162-165; b) polipeptida koji imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 142-145 i 162-165, pod uvjetom da: i) prva sekvenca aminokiseline koja obuhvaća navedeni polipeptid ima Asparaginsku kiselinu (Asp, D) na položaju 1; i ii) polipeptid veže protein F iz hRSV s istim ili višim afinitetom, pri se čemu navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili polipeptid ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi s polipeptidom bez 3, 2 ili 1 razlikom u aminokiselini, c) SEQ ID Br.: 77-79 i 158; d) polipeptida koji imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 77-79 i 158, pod uvjetom da: i) sekvence amino kiselina koje obuhvaća navedeni polipeptid imaju Glutamin (Gln, Q) na položaju 105, Leucin (Leu, L) na položaju 78, Arginin (Arg, R) na položaju 83 i/ili Glutaminsku kiselinu (Glu, E) na položaju 85, pri čemu se navedeni položaji određuju prema Kabatovom numeriranju; i ii) polipeptide veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili polipeptid ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi s polipeptidom bez 3, 2 ili 1 razlikom u aminokiselini, e) SEQ ID Br.: 159-161; f) polipeptida koji imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 159-161, pod uvjetom da: i) sekvenca amino kiseline koja je obuhvaćena u navedenom polipeptidu ima Prolin (Pro, P) na položaju 14, Arginin (Arg, R) na položaju 19, Leucin (Leu, L) na položaju 20 i Leucin (Leu, L) na položaju 108, pri čemu se navedeni položaji određuju prema Kabatovom numeriranju; i ii) polipeptid veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili polipeptid ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi s polipeptidom bez 3, 2 ili 1 razlikom u aminokiselini; (B) trovalentnog polipeptida koji sadrži ili se sastoji od tri sekvence aminokiseline koje obuhvaćaju 4 okvirne regije i 3 regije koje određuju komplementarnost (CDR) u kojem: - CDR1 je SEQ ID NO: 98; i - CDR2 je SEQ ID NO: 102; i - CDR3 je SEQ ID NO: 121, (C) trovalentnog polipeptida koji sadrži ili se sastoji od tri sekvence aminokiseline, pri čemu je svaka amino sekvenca aminokiseline odabrana od slijedećeg a) do d): a) SEQ ID Br.: 60-76; b) sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 60-76, pod uvjetom da: i) sekvenca amino kiseline ima Glutamin (Gln, Q) na položaju 105, pri čemu se navedeni položaj određuje prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini, c) SEQ ID Br.: 146-153; d) sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 146-153, pod uvjetom da: i) sekvenca amino kiseline ima Prolin (Pro, P) na položaju 14, Arginin (Arg, R) na položaju 19, Leucin (Leu, L) na položaju 20 i Leucin (Leu, L) na položaju 108, pri čemu se navedeni položaji određuju prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini.
2. Trovalentni polipeptid prema zahtjevu 1, naznačen time da sadrži ili se sastoji od SEQ ID NO: 53, - pri čemu je prva glutaminska kiselina promijenjena je u asparaginsku kiselinu, te u kojoj u barem jednoj VHH sekvenci koja tvori dio od SEQ ID NO: 53, jedan ili više mutiranih aminokiselinskih ostataka su odabrani od sljedećih: Val5Leu, Ala14Pro, Ser19R, Ile20Leu, Glu44Gly, Ala74Ser, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu i Gly54Asp; ili - u kojoj u barem jednoj VHH sekvenci koja tvori dio od SEQ ID NO: 53, jedan ili više mutiranih aminokiselinskih ostataka su odabrani od sljedećih: Val5Leu, Ala14Pro, Ser19R, Ile20Leu, Glu44Gly, Ala74Ser, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu i Gly54Asp.
3. Trovalentni polipeptid prema bilo kojem od zahtjeva 1 do 2, naznačen time da sadrži ili se sastoji od SEQ ID NO: 53, u kojoj za barem jednu VHH sekvencu koja tvori dio od SEQ ID NO: 53, su mutirani slijedeći ostatci amino kiselina: - Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln i Gln108Leu; - Ala83Arg, Asp85Glu, Arg105Gln i Gln108Leu; - Gly78Leu, Ala83Arg, Asp85Glu i Arg105Gln; - Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu i Gly54Asp; - Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu i Gly54Asp; - Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln i Gly54Asp; - Gly54Asp; - Ala14Pro, Ser19Arg, Ile20Leu i Gln108Leu; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu i Ala83Arg; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu i Asp85Glu; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu i Arg105Gln; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg i Asp85Glu; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108leu, Ala83Arg i Arg105Gln; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu i Arg105Gln; - Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu i Arg105Gln. - Glu1Asp; - Glu1Asp, Va15Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln i Gln108Leu; - Glu1Asp, Ala83Arg, Asp85Glu, Arg105Gln i Gln108Leu; - Glu1Asp, Gly78Leu, Ala83Arg, Asp85Glu i Arg105Gln; - Glu1Asp, Val5Leu, Ala14Pro, Glu44Gly, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu i Gly54Asp; - Glu1Asp, Ala83Arg, Asp85Glu, Arg105Gln, Gln108Leu i Gly54Asp; - Glu1Asp, Gly78Leu, Ala83Arg, Asp85Glu, Arg105Gln i Gly54Asp; - Glu1Asp i Gly54Asp; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu i Gln108Leu; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu i Ala83Arg; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu i Asp85Glu; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu i Arg105Gln; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg i Asp85Glu; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg i Arg105Gln; - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Asp85Glu i Arg105Gln; ili - Glu1Asp, Ala14Pro, Ser19Arg, Ile20Leu, Gln108Leu, Ala83Arg, Asp85Glu i Arg105Gln.
4. Trovalentni polipeptid prema bilo kojem od zahtjeva 1 do 3, naznačen time da sadrži ili se sastoji od jedne od SEQ ID Br.: 77-79, 142-145 i 158-165.
5. Postupak priprave trovalentnog polipeptida prema bilo kojem od zahtjeva 1 do 4, te navedeni postupak sadrži barem korake povezivanja tri jednovalentne aminokiselinske sekvence ili jednovalentnih konstrukata koji su odabrani od: a) SEQ ID Br.: 60-76; b) sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 60-76, pod uvjetom da: i) sekvenca amino kiseline ima Glutamin (Gln, Q) na položaju 105, pri čemu se navedeni položaj određuje prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini; c) SEQ ID Br.:146-153; d) sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 146-153, pod uvjetom da: i) sekvenca amino kiseline ima Prolin (Pro, P) na položaju 14, Arginin (Arg, R) na položaju 19, Leucin (Leu, L) na položaju 20 i Leucin (Leu, L) na položaju 108, pri čemu se navedeni položaji određuju prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini, e) SEQ ID Br.: 138-141 i 154-157; f) sekvenci amino kiselina koje imaju ne više od 3, poželjno ne više od 2, poželjnije ne više od 1 razlike aminokiselina s jednom od SEQ ID Br.: 138-141 i 154-157, pod uvjetom da: i) sekvenca amino kiseline ima asparaginsku kiselinu (Asp, D) na položaju 1, pri čemu se navedeni položaj određuje prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini, i na primjer jednu ili više poveznica.
6. Nukleinska kiselina ili nukleotidna sekvenca, naznačena time da kodira polipeptid prema bilo kojem od zahtjeva 1 do 4.
7. Domaćin ili stanica domaćin naznačena time da izražava polipeptid prema bilo kojem od zahtjeva 1 do 4, i/ili koja sadrži nukleinsku kiselinu ili nukleotidnu sekvencu prema zahtjevu 6.
8. Pripravak naznačen time da sadrži polipeptid prema bilo kojem od zahtjeva 1 do 4, ili nukleinsku kiselinu ili nukleotidnu sekvencu prema zahtjevu 6.
9. Pripravak prema zahtjevu 8, naznačen time da je farmaceutski pripravak.
10. Farmaceutski pripravak naznačen time da sadrži polipeptid prema bilo kojem od zahtjeva 1 do 4, te nosač prikladan za plućnu isporuku.
11. Postupak za proizvodnju polipeptida prema bilo kojem od zahtjeva 1 do 4, ili pripravka prema bilo kojem od zahtjeva 8 ili 9, te navedeni postupak barem sadrži korake: a) eksprimiranje, u pogodnoj stanici domaćinu ili organizmu domaćina ili u drugom pogodnom sustavu za eksprimiranje, nukleinske kiseline ili nukleotidne sekvence prema zahtjevu 6, ili kultiviranje i/ili održavanje domaćina ili stanice domaćina prema zahtjevu 7 pod uvjetima koji su takvi da navedeni domaćin ili stanica domaćin eksprimira i/ili proizvodi polipeptid prema bilo kojem od zahtjeva 1 do 4, ili pripravak prema bilo kojem od zahtjeva 8 ili 9, nakon čega proizvoljno slijedi: b) izoliranje pročišćavanje i/ili pročišćavanje tako dobivenog polipeptida prema bilo kojem od zahtjeva 1 do 4.
12. Polipeptid prema bilo kojem od zahtjeva 1 do 4 i/ili pripravak prema bilo kojem od zahtjeva 8 ili 9 naznačen time da je za uporabu u prevenciji i/ili liječenju barem jednog od respiratorne bolesti, infekcije gornjih dišnih putova, infekcije donjih dišnih putova, bronhiolitisa, upale pluća, dispneje, kašlja, teškog disanja i astme.
13. Farmaceutski uređaj prikladan za plućnu isporuku naznačen time da sadrži polipeptid prema bilo kojem od zahtjeva 1 do 4.
14. Farmaceutski uređaj prema zahtjevu 13 koji je inhalator za tekućine, aerosol ili inhalator sa suhim prahom, naznačen time da sadrži polipeptid prema bilo kojem od zahtjeva 1 do 4.
HRP20171194TT 2009-06-05 2017-08-02 Trovalentni konstrukti nanotijela protiv ljudskog respiratornog sincicijskog virusa (hrsv) za prevenciju i/ili liječenje infekcija dišnih puteva HRP20171194T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18439609P 2009-06-05 2009-06-05
US26501409P 2009-11-30 2009-11-30
PCT/EP2010/057921 WO2010139808A2 (en) 2009-06-05 2010-06-07 IMPROVED AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (hRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS
EP10724497.2A EP2438087B1 (en) 2009-06-05 2010-06-07 Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections

Publications (1)

Publication Number Publication Date
HRP20171194T1 true HRP20171194T1 (hr) 2017-10-20

Family

ID=42333502

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171194TT HRP20171194T1 (hr) 2009-06-05 2017-08-02 Trovalentni konstrukti nanotijela protiv ljudskog respiratornog sincicijskog virusa (hrsv) za prevenciju i/ili liječenje infekcija dišnih puteva

Country Status (25)

Country Link
US (3) US8945567B2 (hr)
EP (2) EP2438087B1 (hr)
JP (2) JP6081196B2 (hr)
KR (1) KR101852204B1 (hr)
CN (2) CN105061592A (hr)
AU (1) AU2010255638B2 (hr)
BR (1) BRPI1010830A2 (hr)
CA (1) CA2764398A1 (hr)
CY (1) CY1119265T1 (hr)
DK (1) DK2438087T3 (hr)
ES (1) ES2643034T3 (hr)
HR (1) HRP20171194T1 (hr)
HU (1) HUE035773T2 (hr)
IL (1) IL216341A0 (hr)
LT (1) LT2438087T (hr)
MX (1) MX340541B (hr)
NZ (1) NZ597314A (hr)
PH (1) PH12019500644A1 (hr)
PL (1) PL2438087T3 (hr)
PT (1) PT2438087T (hr)
RU (2) RU2577134C2 (hr)
SG (1) SG176095A1 (hr)
SI (1) SI2438087T1 (hr)
WO (1) WO2010139808A2 (hr)
ZA (1) ZA201108892B (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2285408T (pt) 2008-06-05 2019-02-01 Ablynx Nv Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
DK2438087T3 (en) 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011073180A1 (en) 2009-12-14 2011-06-23 Ablynx N.V. Single variable domain antibodies against ox40l, constructs and therapeutic use
PL3501499T3 (pl) 2010-02-11 2023-01-09 Ablynx Nv Sposoby i kompozycje do wytwarzania aerozoli
EP3279214A1 (en) 2010-10-29 2018-02-07 Ablynx NV Method for the production of immunoglobulin single variable domains
WO2012152823A1 (en) 2011-05-09 2012-11-15 Ablynx Nv Method for the production of immunoglobulin single variable domains
US11339208B1 (en) 2012-05-31 2022-05-24 United States Of America As Represented By The Secretary Of The Air Force Camelidae single-domain antibodies against Yersinia pestis and methods of use
MX2015012709A (es) 2013-03-14 2016-05-31 Macrogenics Inc Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
BR112016003348B1 (pt) 2013-08-21 2023-03-07 Alios Biopharma, Inc Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos
US20160045528A1 (en) * 2014-08-05 2016-02-18 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
RU2700650C2 (ru) 2014-10-10 2019-09-18 Аблинкс Н.В. Игаляционное устройство для использования в аэрозольной терапии респираторных заболеваний
JP2017538779A (ja) * 2014-10-10 2017-12-28 アブリンクス・エヌ・フェー Ｒｓｖ感染の治療方法
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
EP3124042A1 (en) * 2015-07-28 2017-02-01 VIB, vzw Immunoglobulin single variable domain antibody against rsv prefusion f protein
KR20180056631A (ko) * 2015-06-18 2018-05-29 브이아이비 브이지더블유 Rsv 프리퓨전 f 단백질에 대한 면역글로불린 단일 가변 도메인 항체
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
BR112018076569A2 (pt) 2016-06-23 2019-04-02 Ablynx Nv ensaios farmacocinéticos melhorados para domínios variáveis simples de imunoglobulina
CN106279410B (zh) * 2016-09-29 2019-08-20 华南理工大学 一种二型登革热病毒ns1蛋白多价纳米抗体及制备方法
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JP2020503843A (ja) 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
BR112019008063A2 (pt) 2016-10-21 2019-07-02 Adimab Llc anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
AU2018346978B2 (en) 2017-10-13 2024-02-15 Mapp Biopharmaceutical, Inc. Anti-respiratory syncytial virus antibodies, methods of their generation and use
JP7123607B2 (ja) * 2018-04-09 2022-08-23 シャープ株式会社 ユーザ装置、制御装置、及び通信制御方法
CN113993898A (zh) 2019-04-10 2022-01-28 瑞泽恩制药公司 结合ret的人抗体及其使用方法
CN111748571B (zh) * 2019-10-11 2022-05-03 浙江禾霖生物科技有限公司 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法
EP4065601A1 (en) 2019-11-25 2022-10-05 Mabloc, LLC Anti-yellow fever virus antibodies, and methods of their generation and use
US20210230248A1 (en) * 2020-01-25 2021-07-29 Jun Chen Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof
CN116693673B (zh) * 2023-07-26 2023-10-20 中国人民解放军军事科学院军事医学研究院 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120945A (en) 1964-08-11 1968-07-24 Fisons Pharmaceuticals Ltd Applicator in combination with a pressurised aerosol dispensing container
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2078518T3 (es) 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
JP3626187B2 (ja) 1993-06-07 2005-03-02 バイカル インコーポレイテッド 遺伝子治療に適するプラスミド
DK0702721T3 (da) 1993-06-09 2001-05-21 Unilever Nv Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0851874B1 (en) 1995-09-22 1999-09-15 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
JP2001510329A (ja) * 1996-11-01 2001-07-31 スミスクライン・ビーチャム・コーポレイション ヒトモノクローナル抗体
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
WO1998022141A2 (en) 1996-11-19 1998-05-28 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
FR2766826B1 (fr) 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
CA2321199A1 (en) 1998-02-19 1999-08-26 William A. Brady Compositions and methods for regulating lymphocyte activation
GB9824632D0 (en) 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
EP1157119A1 (en) 1999-02-05 2001-11-28 Rijksuniversiteit Leiden Method of modulating metabolite biosynthesis in recombinant cells
AU776824B2 (en) 1999-04-22 2004-09-23 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
AR030019A1 (es) * 1999-05-18 2003-08-13 Smithkline Beecham Corp Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m
WO2001009300A2 (en) 1999-08-02 2001-02-08 Keygene N.V. Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
AU784285B2 (en) 1999-12-24 2006-03-02 Genentech Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CN1911965B (zh) 2001-01-17 2013-05-29 新兴产品开发西雅图有限公司 结合域-免疫球蛋白融合蛋白
EP1377306A1 (en) 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
WO2003014960A2 (en) 2001-08-03 2003-02-20 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
FR2829940A1 (fr) 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2468690A1 (en) 2001-12-18 2003-06-26 Innogenetics N.V. Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ATE328906T1 (de) 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
US7521543B2 (en) 2002-10-23 2009-04-21 Ludwig Institute For Cancer Research A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
WO2010081856A1 (en) 2009-01-14 2010-07-22 Ablynx Nv Pulmonary administration of immunoglobulin single variable domains and constructs thereof
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
GB0230203D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
DE60329627D1 (de) 2002-12-31 2009-11-19 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
US7070786B2 (en) 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
AU2004254352A1 (en) 2003-06-27 2005-01-13 Roberto Crea Look-through mutagenesis
CA2529819A1 (en) 2003-06-30 2004-09-23 Domantis Limited Pegylated single domain antibodies
JP2008530626A (ja) 2003-06-30 2008-08-07 シーメンス アクチエンゲゼルシヤフト マイクロコンピュータにおけるプログラムの実行を監視する方法
JP2007521234A (ja) 2003-08-12 2007-08-02 ウィリアム エム ヤーブロー 尋常性ざ瘡の治療薬及び使用方法
EP1512696A1 (en) 2003-08-14 2005-03-09 Diatos Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
EP1720908A2 (en) * 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US7207410B2 (en) 2004-04-29 2007-04-24 Daimlerchrysler Corporation Apparatus and method for enhanced impact sensing
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
WO2006023144A2 (en) 2004-07-06 2006-03-02 Bioren Inc. Look-through mutagenesis for developing altered polypeptides with enhanced properties
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006034292A2 (en) 2004-09-21 2006-03-30 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
KR20070084170A (ko) 2004-10-13 2007-08-24 아블린쓰 엔.브이. 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
CA2585891A1 (en) 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
AU2005311101B8 (en) * 2004-12-02 2011-03-03 Domantis Limited Anti-IL-IRI single domain antibodies and therapeutic uses
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
JP4976376B2 (ja) 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
AU2007293614A1 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
AU2007306340A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and use thereof
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
CN101611056A (zh) 2006-12-05 2009-12-23 埃博灵克斯股份有限公司 能够结合于血清蛋白的肽
CA2672944A1 (en) 2006-12-22 2008-07-03 Ablynx N.V. Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
US10214588B2 (en) 2007-07-03 2019-02-26 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
EP2096121A1 (en) 2008-02-29 2009-09-02 Institut Pasteur Of Shanghai Antiviral peptides comprising lipid attachment signals and methods of use
PT2285408T (pt) * 2008-06-05 2019-02-01 Ablynx Nv Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
HUE053480T2 (hu) 2009-04-30 2021-06-28 Ablynx Nv Eljárás domén ellenanyagok elõállítására
DK2438087T3 (en) 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections

Also Published As

Publication number Publication date
CY1119265T1 (el) 2018-02-14
RU2011153239A (ru) 2013-07-20
US20150118233A1 (en) 2015-04-30
ZA201108892B (en) 2013-05-29
WO2010139808A3 (en) 2011-02-24
KR20140015113A (ko) 2014-02-06
IL216341A0 (en) 2012-01-31
JP6081196B2 (ja) 2017-03-01
US20120128669A1 (en) 2012-05-24
BRPI1010830A2 (pt) 2023-11-14
JP6677659B2 (ja) 2020-04-08
CN102459332B (zh) 2015-08-19
AU2010255638A1 (en) 2012-01-12
CN102459332A (zh) 2012-05-16
EP2438087B1 (en) 2017-05-10
DK2438087T3 (en) 2017-08-28
SI2438087T1 (sl) 2017-10-30
EP3205670A1 (en) 2017-08-16
SG176095A1 (en) 2011-12-29
HUE035773T2 (en) 2018-05-28
RU2016103067A (ru) 2018-11-20
LT2438087T (lt) 2017-08-25
RU2577134C2 (ru) 2016-03-10
WO2010139808A2 (en) 2010-12-09
US9803001B2 (en) 2017-10-31
JP2012528584A (ja) 2012-11-15
PH12019500644A1 (en) 2020-10-12
NZ597314A (en) 2013-07-26
KR101852204B1 (ko) 2018-04-26
US11028151B2 (en) 2021-06-08
CN105061592A (zh) 2015-11-18
CA2764398A1 (en) 2010-12-09
US20180105581A1 (en) 2018-04-19
JP2017093460A (ja) 2017-06-01
RU2016103067A3 (hr) 2019-08-08
PT2438087T (pt) 2017-08-04
AU2010255638B2 (en) 2014-10-16
ES2643034T3 (es) 2017-11-21
MX340541B (es) 2016-07-13
US8945567B2 (en) 2015-02-03
EP2438087A2 (en) 2012-04-11
PL2438087T3 (pl) 2017-10-31
MX2011013013A (es) 2012-01-30

Similar Documents

Publication Publication Date Title
HRP20171194T1 (hr) Trovalentni konstrukti nanotijela protiv ljudskog respiratornog sincicijskog virusa (hrsv) za prevenciju i/ili liječenje infekcija dišnih puteva
JP2012528584A5 (hr)
HRP20192160T1 (hr) Vezujući proteini serumskog albumina
US10370435B2 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
TWI637965B (zh) 結合到ｒｓｖ ｇ蛋白之人類抗體
HRP20190714T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
TWI539963B (zh) 抗－人類呼吸道融合性病毒（ｒｓｖ）抗體及其使用方法
JP2018537421A5 (hr)
CN105722856B (zh) Rsv融合蛋白的表位以及识别其的抗体
AU2019323389B2 (en) Anti-BCMA single domain antibodies and application thereof
JP2017529097A5 (hr)
TW200911832A (en) Polypeptides, antibody variable domains & antagonists
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
TW201534619A (zh) 結合到ｒｓｖ ｇ蛋白之人類抗體
CN107029227A (zh) 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途
JP2021112193A (ja) 中和抗インフルエンザ結合分子及びその使用
JP2013502204A5 (hr)
HRP20191590T1 (hr) Protutijela za bubrežni antigen 1 i njihov fragment koji veže antigen
CN113045647A (zh) 新冠病毒SARS-CoV-2的中和性抗体及其应用
US11248039B2 (en) Immunoglobulin single variable domain antibody against RSV prefusion F protein
Henry et al. A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders
CN106397582A (zh) Hpv16e7蛋白纳米抗体及其制备方法与应用
EP3124042A1 (en) Immunoglobulin single variable domain antibody against rsv prefusion f protein
CA2745598A1 (en) Fully human influenza m2 specific antibodies
CN115427441B (zh) 针对sars-cov-2的抗体